利妥昔单抗是治疗老年难治性温抗体型自身免疫性溶血性贫血（AIHA）复发的一种有效且安全的疗法。
Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA.
作者信息
Laribi Kamel, Bolle Delphine, Ghnaya Habib, Sandu Andrea, Besançon Anne, Denizon Nathalie, Truong Catherine, Pineau-Vincent Fabienne, de Materre Alix Baugier
机构信息
Department of Haematology, Centre Hospitalier, 194 Avenue Rubillard, 72000, Le Mans, France.
Pharmacy Department, Centre hospitalier, Le Mans, France.
出版信息
Ann Hematol. 2016 Apr;95(5):765-9. doi: 10.1007/s00277-016-2605-2. Epub 2016 Feb 9.
We evaluated the efficacy and safety of rituximab for the treatment of 23 elderly patients (median age 78 years) with warm autoimmune haemolytic anaemia (AIHA). The median follow-up was 31 months. Patients had received one to five previous treatments. Rituximab was administered by intravenous infusion at a dose of 375 mg/m(2) once weekly for 4 weeks. The OR rate was 86.9 % (CR = 39.1 %, PR = 47.8 %). Median OS was 87 months. The median OS of patients who reached CR could not be calculated, and that of patients with PR was 67 months. At last follow-up, eight of the 20 responding patients, including one patient in CR and seven in PR, had relapsed after a median of 6 months. Failure to achieve CR was a risk factor for relapse (p = 0.028). We did not identify any pretreatment characteristics predictive of response to rituximab. In conclusion, rituximab is an effective treatment for elderly patients with refractory warm AIHA.
我们评估了利妥昔单抗治疗23例老年温抗体型自身免疫性溶血性贫血（AIHA）患者（中位年龄78岁）的疗效和安全性。中位随访时间为31个月。患者此前接受过1至5次治疗。利妥昔单抗通过静脉输注给药，剂量为375 mg/m²，每周1次，共4周。总缓解率为86.9%（完全缓解率=39.1%，部分缓解率=47.8%）。中位总生存期为87个月。达到完全缓解的患者的中位总生存期无法计算，部分缓解患者的中位总生存期为67个月。在最后一次随访时，20例缓解患者中有8例复发，包括1例完全缓解患者和7例部分缓解患者，中位复发时间为6个月。未达到完全缓解是复发的一个危险因素（p=0.028）。我们未发现任何预测利妥昔单抗疗效的预处理特征。总之，利妥昔单抗是治疗老年难治性温抗体型AIHA的有效疗法。
Zotero 插件